Organon and Viatris' patent expired drugs remain powerful. Although questions have been raised about the growth engines of the two independent corporations after receiving "old drugs" from MSD and Pfizer, it is evaluated that it is as good as in Korea.

◆Organon's Atozet and Cozaar's outpatient prescription is 250 billion won

According to UBIST, a drug research institute, on the 28th, Organon, which was launched in June last year, exerted the power of patent-expired drugs. Last year, Organon's outpatient prescription estimate was 252.4 billion won. This is the sum of the outpatient prescriptions for items transferred to Organon among MSD products. It accounts for 58% of the 437.5 billi